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Objective: To investigate whether the N-acetyltransferase 2 (NAT2) 
gene is involved in the development of susceptibility to antituberculosis 
drug-induced liver damage (ATDLI) in patients with pulmonary tubercu-
losis in the Han nationality. Methods: We retrospectively analyzed 300 
cases of tuberculosis patients without liver damage (control group) and 
221 cases of tuberculosis patients with liver damage after antituberculosis 
treatment (case group). After antituberculosis treatment, genetic poly-
morphisms of NAT2 were analyzed in those patients using MassARRAY 
method. Results: Of the 10 tagged SNPs selected, In the promoter area of 
NAT2, the frequencies of T allele in rs4646243 and A allele in rs4646246 
were signi cantly higher in the patients with ATDLI than controls (0.569 
vs. 0.483, p=0.0062 and 0.567 vs 0.487, p=0.0103). The A allele of 
rs1115784 in the intron area showed a significant association with the 
development of ATDLI (0.389 vs 0.305, p = 0.0043). The frequencies 
of the mutated genes T and A in rs1041983 and rs1799930 in the second 
exon region were significantly higher than those in the control group 
(0.491 vs 0.360, p<0.00001 and 0.336 vs 0.212, respectively; p<0.00001).
Two monomer domains were found in the 10 tag SNP sites, haplotype ht 
[TGAA] in monomeric domain 1 and haplotype ht [TAG] in monomeric 
domain 2, both were signi cantly more likely to be detected in the liver 
injury group than in the control group(p=0.0038, p<0.001, respectively). 
Two haplotypes were also found on the NAT2 gene: haplotype ht [CGGG] 
in monomeric domain 1 and ht [CGG] in block 2, and their presence 
means a lower risk of liver damage. Conclusion: NAT2 genotypes might 
have signi cant association with the risk of ATDLI in the Chinese Han 
nationality. By detecting the NAT2 gene and its haplotype, we can screen 
patients with a higher risk of liver damage before anti-TB treatment and 
take measures for the protection of patients.
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1. Introduction
O
verall, 5-15% of the estimated 1.7 billion people 
infected with M. tuberculosis will develop TB dis-
ease. However, among people infected with HIV, 
the probability of developing TB disease is much higher, 
other risk factors include under-nutrition, diabetes, smok-
ing and alcohol consumption, etc. Currently, short-course 
chemotherapy for tuberculosis with isoniazid, rifampicin, 
ethambutol and pyrazinamide as the core is adopted[1]. A 
large number of clinical studies have shown that isoniazid, 
rifampicin and pyrazinamide are all likely to cause liver 
damage. Especially when they are used in combination, the 
incidence and severity of liver damage increase signi cant-
ly[2-5]. Many risk factors are associated with the occurrence 
of hepatic damage caused by antituberculosis drugs, such 
as females, advanced age, HIV infection, hypoalbumin-
emia, alcoholism, hepatitis B or hepatitis C virus infection, 
and severe lung diseases with tuberculosis, etc[6-9]. Hepatic 
damage is the result of the complex interaction of these risk 
factors. However, when these risk factors are removed or 
balanced the risk of liver damage between different indi-
viduals is still very different, indicates that the individual’s 
susceptibility may be the most important factor. In recent 
years molecular epidemiological studies have found a 
link between polymorphisms in certain drug-metaboliz-
ing enzyme genes and susceptibility to antituberculosis 
drug-induced liver damage [4,5,10], of which, phase II enzyme 
N-acetyltransferase 2 (NAT2) , the  rst enzyme in isoniazid 
metabolism, was considered as a target enzyme in the study 
of genetic polymorphisms and antituberculosis drug-in-
duced liver damage[11,12].
In this report, using MassARRAY technology, a 
case-control study was conducted to investigate the rela-
tionship between NAT2 gene polymorphism and suscepti-
bility to antituberculosis drug-induced liver damage in the 
Chinese Han nationality.
2. Research Objects and Methods
2.1 Research Objects
A total of 528 patients with primary and recurrent tuber-
culosis who met the inclusion criteria from May 2010 to 
March 2016 were recruited. After a retrospective analysis, 
the patients were divided into two groups, including 228 
patients in the case group, who had liver damage after re-
ceiving  rst-line antituberculosis treatment (2HRZE/4HR). 
Antituberculosis drug-induced liver damage is de ned as 
asymptomatic or hepatic symptoms after taking antituber-
culosis drugs, such as loss of appetite, nausea, and vom-
iting, etc., and includes at least one of the following con-
ditions: (1) Serum AST and/or ALT is more than 2 times 
the upper limit of normal (ULN) (or > 80 U/L), (2) Any 
increase in ALT, AST is accompanied by progressively 
elevated bilirubin (>2.5 mg/dl). A total of 300 tuberculosis 
patients taking the same antituberculosis drugs without 
drug-induced liver damage were selected as the control 
group. All patients included in the study were required to 
meet the following criteria: normal liver function tests at 
the beginning of chemotherapy and exclusion of any other 
factors that may cause liver damage, such as malnutrition, 
HIV infection, alcohol abuse, viral hepatitis, liver disease, 
cardiac insuf ciency, and no use of other drugs that may 
cause liver damage, etc. During the course of treatment, 
the enrolled patients were asked to be closely monitored 
for changes in their liver function.
2.2 Methods
2.2.1 DNA Extraction from Human Peripheral 
Blood Mononuclear Cells
A peripheral blood sample of the above-mentioned tuber-
culosis patient was collected. DNA of the mononuclear 
cells in those samples was extracted using the whole ge-
nome DNA extraction kit (Tiangen Biotech, Beijing,Chi-
na) according to the instructions and were immediately 
stored in a refrigerator at -20°C.
2.2.2 Selection of NAT2 Gene SNPs and Detection 
of Their Polymorphisms
According to the gene polymorphism published in the 
public SNP database and related literature reports, 10 
tag SNP loci from the NAT2 gene of the Chinese Han 
nationality, were screened using haploview4.2 software. 
See Table 1 for details. Mass spectrometry (MassARRAY, 
Sequenom, USA) was used to detect the genotype of each 
SNP locus.
2.2.3 Statistical Analysis
Using SPSS 13.0 and haploview 4.2 software, t-test, x2 
test and other statistical methods were used to analyze the 
basic parameters of the case group and the control group. 
Pearson’s chi-square test or Fisher’s exact test was used to 
analyze the distribution of genotypes and alleles at each site 
in the case and control groups. The test level is α=0.05.
3. Results
3.1 Analysis of the Basic Characteristics of the 
Two Groups
There was no statistically signi cant difference in gen-
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der and age between the case group and the control group. 
The values of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), direct bilirubin (DBIL) and total 
bilirubin (TBIL) before administration were all within 
the normal range. Hardy-Weinberg equilibrium in control 
group, MAF test of all data, the percentage of non-dele-
tional genotypes in the locus, and other gene locus related 
information are shown in Table 1.
Table 1. The basic of the 10 SNP loci
Name Position
ObsH-
ET
Pred-
HET
HWpval %Geno MAF Alleles
rs4646243 18291889 0.498 0.499 0.2496 99.4 0.48 T:C
rs4271002 18292548 0.281 0.286 1 100 0.173 G:C
rs4646246 18292941 0.495 0.499 0.3619 99.2 0.479 A:G
rs1115784 18299690 0.466 0.45 0.5332 99.8 0.341 G:A
rs1041983 18302075 0.483 0.486 0.0191 99.8 0.416 C:T
rs1801280 18302134 0.087 0.084 1 99.8 0.044 T:C
rs1799929 18302274 0.083 0.08 1 100 0.042 C:T
rs1799930 18302383 0.382 0.39 0.1749 99.8 0.265 G:A
rs1208 18302596 0.084 0.08 1 99.8 0.042 A:G
rs1799931 18302650 0.247 0.247 0.9113 100 0.144 G:A
Notes:
• Position: Position of the locus on the chromosome;
• %Geno: The percentage of non-deleted genotypes on the locus for all 
samples (the minimum value is 75%, less than this value is considered to 
have failed the test);
• MAF: The frequency of the last allele at this site (minimum value is 
0.001, less than this value is considered to have failed the test);
• Alleles: major and minor alleles at the locus.
3.2 Analysis of Individual SNP and ATDLI
The differences in the distribution of genotypes and alleles 
at each site between the case group and the control group 
were analyzed using the Pearson chi-square test or Fish-
er’s exact test. The results are shown in Table 2. As can 
be seen from the chart, there are statistically significant 
differences in the alleles of the NAT2 gene at the  ve SNP 
loci in the case group and the control group: rs4646243, 
rs4646246, rs1115784, rs1041983, and rs1799930. Among 
the  ve SNPs in NAT2, the T allele in the promoter region 
rs4646243 and the A allele in rs4646246 were signi cantly 
more frequently expressed in patients with antituberculous 
drug-induced hepatic impairment than in the control group 
(0.569 vs 0.483, p=0.0062 and 0.567 vs 0.487, p=0.0103, 
respectively), indicating that they both increased the risk 
of liver damage. In rs1115784, which was located in the 
first intron region, the frequency of its A allele in the 
case group was also higher than that in the control group 
(0.389 vs 0.305, p = 0.0043). The frequency of T allele 
in rs1041983, located in the second exon region, was 
signi cantly higher in the case group than in the control 
group (0.491 vs 0.360, p<0.00001). However, this SNP 
change does not cause codon changes, and the expression 
product is a tyrosine-containing protein. Rs1799930 is 
also located in the second exon region of the NAT2 gene. 
The frequency of A allele is not only signi cantly higher 
in the case group than in the control group (0.336 vs 0.212, 
p<0.00001), but also this mutation makes the 197th code 
of the NAT2 gene changed from arginine to glutamine, 
The tertiary structure of proteins may therefore be altered.
Table 2. Differences in distribution of genotypes and 
alleles between case group and control group
Site Alleles
Number of cases
(case,control)
Frequency
(case,control)
χ2 P
rs4646243 T
257:195, 
288:308
0.569, 0.483 7.504 0.0062
rs4271002 C 79:375, 103:497 0.174, 0.172 0.01 0.9206
rs4646246 A
255:195, 
290:306
0.567, 0.487 6.59 0.0103
rs1115784 A
176:276, 
183:417
0.389, 0.305 8.165 0.0043
rs1041983 T
222:230, 
216:384
0.491, 0.360 18.247
1.94E-
05
rs1801280 T 436:18, 570:28 0.960, 0.953 0.318 0.573
rs1799929 C 436:18, 574:26 0.960, 0.957 0.088 0.767
rs1799930 A
152:300, 
127:473
0.336, 0.212 20.543
5.83E-
06
rs1208 A 437:17, 571:27 0.963, 0.955 0.382 0.5363
rs1799931 A 68:386, 84:516 0.150, 0.140 0.2 0.6545
3.3 Analysis of Linkage Disequilibrium
In a certain population, the frequency at which two alleles 
at different loci appear on the same chromosome is higher 
than the expected random frequency. This phenomenon 
is de ned as linkage disequilibrium. A non-random com-
bination of certain alleles of this different locus is often 
inherited together. By using D’/r^2 and other methods to 
investigate the linkage disequilibrium between loci, it was 
found that there are 2 monomer domains in 10 sites of 
NAT2 gene, and there is a linkage disequilibrium in some 
sites in each monomer domain. The specific results are 
shown in Fig. 1. Above the monomer domain, we marked 
the rs number of the locus, which makes it easy to see 
which speci c rs-sites have haplocells.
DOI: https://doi.org/10.30564/jams.v2i3.754
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Figure 1. Pairing LDs between SNPs in a gene cluster
The value of each square represents the correlation co-
ef cient of the tag’s top-left and top-right SNPs. No data 
on the grid represents D’=1. A bold square represents hap-
lotype formation in that particular SNP site.
3.4 Haplotype Analysis
A set of single nucleotide polymorphisms that are related 
to each other in a specific region of a chromosome and 
tend to be inherited globally to offspring, were known as 
haplotypes. For the monomer domain detected in the above 
linkage disequilibrium analysis, The distribution ratios of 
haplotypes in each monomer domain in the case group and 
the control group were calculated separately, Pearson’s chi-
square test was used to examine the association between 
overall genetic haplotype and disease (p<0.05). The results 
are shown in Table 3. Four haplotypes closely related to an-
tituberculosis drug-induced hepatic impairment were found 
in two monomer domains consisting of 10 SNPs. Among 
them, the haplotype ht [TGAA] located in monomeric do-
main 1 and the haplotype ht [TAG] located in monomeric 
domain 2 appeared more often in the case group than in the 
control group (p=0.0043 and p<0.0001, respectively). Two 
haplotypes were also found on the NAT2 gene and were 
associated with a lower risk of liver damage: haplotype ht 
[CGGG] in monomeric domain 1 and ht [CGG] in mono-
meric domain 2.
Table 3. Relationship between haplotype and liver dam-
age
Haplo-
types
Fre-
quency
Number of cases
(case,control)
Frequency
(case,control)
χ2 P
Domain 1
CGGG 0.475
193.0 : 259.0, 307.0 
: 293.0
0.427, 0.512 7.409 0.0065
TGAA 0.341
176.0 : 276.0, 183.0 
: 417.0
0.389, 0.305 8.165 0.0043
TCAG 0.168
77.0 : 375.0, 100.0 : 
500.0
0.170, 0.167 0.026 0.8726
Domain 2
CGG 0.584
231.4 : 222.6, 384.0 
: 216.0
0.510, 0.640 18.083
2.11E-
05
TAG 0.265
152.6 : 301.4, 127.0 
: 473.0
0.336, 0.212 20.553
5.80E-
06
TGA 0.144
68.0 : 386.0, 84.0 : 
516.0
0.150, 0.140 0.2 0.6545
4. Discussion
In the process of isoniazid metabolism, isoniazid is first 
acetylated to acetyl isoniazid by NAT2 and then hydro-
lyzed to produce monoacetyl hydrazine, which is then 
catalyzed by cytochrome P450 2E1 and oxidized to a 
hydroxylamine form, and this intermediate metabolite can 
cause liver damage[13]. In the study of pharmacokinetics, 
the phenotypes of NAT2 were divided into fast acetylated 
genotypes, mid-acetylated genotypes, and slow acetylat-
ed genotypes depending on the rate of acetylation. This 
classi cation is mainly related to genetic polymorphisms, 
and studies have shown that the different NAT2 genotypes 
have a signi cant effect on their metabolic capacity[14-16]. 
The fast-acetylated genotypes convert isoniazid to ace-
tylcholine significantly faster than slow-acetylated gen-
otypes, and by further acetylation, acetyl hydrazine can 
be converted to diacetyl hydrazine, which makes acetyl 
hydrazine, an intermediate metabolite with strong hepa-
totoxicity, not accumulates, thereby increasing detoxifi-
cation ef ciency. On the contrary, in the slow acetylation 
type, the formation of a non-toxic derivative of diacetyl 
hydrazine from acetyl hydrazine may be hindered, which 
favors the formation of more toxic monoacetyl guanidine 
derivatives through cytochrome P450 2E1-mediated me-
tabolism, causing liver damage.
Studies have evaluated the relationship between NAT2 
genotypes and the risk of hepatitis. Through the study 
of 224 tuberculosis patients treated with antitubercu-
lous drugs, Huang et al.[17] reported that the incidence of 
drug-induced liver damage was 14.7%, and the incidence 
of severe liver damage was 6.3%. In the slow acetylation 
genotypes, the risk factors for drug-induced liver dam-
age in the NAT2*6/6 and NAT2*6/7 genotypes were as 
high as 4.02. Compared with fast-acetylated genotypes, 
slow-acetylated genotypes have a high incidence of 
drug-induced liver damage and are more prone to severe 
drug-induced liver damage. The study concluded that 
NAT2 slow acetylation genotypes are important suscep-
tibility factors for the development of antituberculosis 
drug-induced hepatic impairment. In India, Bose et al.[5] 
studied 218 patients with tuberculosis, including 41 pa-
tients with hepatic impairment after treatment, and the 
results showed that the appearance of NAT2*5/*7 and 
NAT2*6/*7 genotypes was signi cantly higher in patients 
with hepatic impairment than in patients without liver 
damage. The investigation of Cho et al.[18] pointed out that 
DOI: https://doi.org/10.30564/jams.v2i3.754
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in the study of 132 patients with tuberculosis in South 
Korea (18 cases of drug-induced hepatotoxicity), the risk 
of liver damage in patients with the NAT2 slow acetyla-
tion genotype is 3.8 times higher than in patients with fast 
acetylation, suggesting that the NAT2 genotype can be 
used as an effective predictor of antituberculosis drug-in-
duced liver damage. Through the study of 50 tuberculosis 
patients in Iran, the results of Khalili et al.[19] also con-
 rmed that the frequency of NAT2 slow acetylation geno-
types in antituberculosis drug-induced hepatic impairment 
is much higher than that of fast acetylation genotypes. 
Wang Jinhe et al.[20] explored NAT2 gene polymorphisms 
in 32 patients with antituberculous drug-induced hepatic 
impairment and 35 patients without liver damage.  The 
results of the study also proved that the NAT2 genotype is 
highly related to isoniazid and rifampin-induced liver dis-
ease, and moreover, the 857 codon mutation may be one 
of the susceptibility genotypes of hepatic toxicity in TB 
patients. However, the above studies only emphasize the 
relationship between the acetylation phenotype and liver 
damage in NAT genotypes, and most studies only veri ed 
the relationship between base mutations in the exon re-
gion of the NAT2 gene and liver damage.[21,22]
In this study, we screened out the target locus accord-
ing to the genotype frequency in the SNP of the Chinese 
population reported in the public SNP database. Most of 
these sites are in the promoter and exon regions, and a few 
are in the intron region. Then, the frequency of each SNP 
locus allele in the case group and the control group was 
measured by the MassARRAY method. Further, we ana-
lyzed the association of these SNP loci and haplotypes with 
antituberculous drug-induced hepatic impairment. When 
analyzing NAT2, we found -9905C>T (rs4646243), -8853 
G > A (rs4646246) in the promoter region, and -2098G>A 
(rs1115784) in the first intron, and in the second exon, 
282C>T (rs1041983), 590G>A (rs1799930), are all signi -
cantly associated with antituberculosis drug-induced liver 
damage. The relationship between the  rst three SNP poly-
morphisms and antituberculosis drug-induced liver damage 
has not been reported before. Kim et al.[23] proposed that in 
the Korean population, if A replaces T at -9796 in the pro-
moter of NAT2 gene,  is closely related to antituberculosis 
drug-induced hepatitis, it is closely related to the occur-
rence of antituberculosis drug-induced hepatitis. Further-
more, in vitro experiments showed that the activity of lucif-
erase containing the A allele was reduced, so it is believed 
that carrying this variant allele in the promoter will reduce 
NAT2 transcriptional activity. We speculate that the -9905 
C>T, -8853 G>A mutation also reduces the expression 
of the NAT2 gene by reducing its transcriptional activity, 
thereby increasing the risk of liver damage. The reason for 
the correlation between the  rst intron -2098 G>A mutation 
and drug-induced liver damage has yet to be confirmed. 
The mutation of 282 C>T, 590 G>A in the second exon 
(according to the international term consensus, also known 
as NAT2*6) increased the risk of occurrence of antituber-
culosis drug-induced liver damage, which is consistent with 
the results of Possuelo et al.[24]. In the study by Possuelo et 
al., 282 T genotypes and NAT2*6/6 genotypes were more 
susceptible to antituberculosis drug-induced liver damage, 
with risk factors of 4.3 and 5.7, respectively (P<0.01). The 
research of Huang et al.[17] also supports this view. Howev-
er, the change of 282 C>T in coding region does not cause 
codon change, and the exact mechanism of the TT genotype 
prone to antituberculosis drug-induced hepatic impairment 
is still unclear. It may be because this base change causes 
a spatial conformational change in the NAT2-encoded pro-
tein, resulting in a change in protein function. The change 
in coding region 590 G>A caused the 197 codon of the 
NAT2 gene to be changed, and the amino acid at this posi-
tion in the encoded protein was changed from arginine to 
glutamine. This leads to changes in the structure and func-
tion of functional proteins, resulting in a reduction in the 
ability of NAT2 enzymes to metabolize, thereby increasing 
the risk of drug-induced liver damage[15,23]. In addition, we 
also found 4 haplotypes closely related to antituberculosis 
drug-induced hepatic impairment in NAT2, of which 2 hap-
lotypes increased the risk of occurrence of hepatic impair-
ment in antituberculosis drugs: haplotypes in monomeric 
domain 1 ht [TGAA] and haplotype ht [TAG] located in 
monomer domain 2. While the other two haplotypes: hap-
lotype ht [CGGG] in monomeric domain 1 and ht [CGG] in 
monomeric domain 2 are suggestive of a lower risk of liver 
damage, and they may play an important role in predicting 
the risk of drug related liver damage.
5. Conclusion
In summary, we used MassARRAY method to analyze 
10 SNP sites in NAT2 and found 5 SNP sites and 4 hap-
lotypes closely related to antituberculosis drug-induced 
liver damage. Therefore, we should be able to screen for 
NAT2 genotypes and haplotypes in TB patients using the 
MassARRAY method to predict the possibility of liver 
damage in that particular patient before taking antituber-
culosis drugs, and thus provide a scienti c basis for indi-
vidualized use of liver protection drugs.
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